← Patent-cliff monitor small molecule NUBEQA DAROLUTAMIDE
Loss of exclusivity June 2042 latest FDA-listed patent expiry
Drug detail Brand name NUBEQA Active ingredient DAROLUTAMIDE Strength 300MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2019 Marketing status RX
Listed patents Patent Expires Type 12329742 June 2042 product 12611397 July 2040 product 11168058 February 2038 substance, product 10835515 January 2036 product 10010530 January 2036 substance 10383853 January 2036 substance 8975254 March 2033 substance, product 9657003 October 2030 substance, product 10711013 October 2030 substance, product 11046713 October 2030 substance
Regulatory exclusivity Code Expires I-971 June 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.